» Articles » PMID: 22133529

Paraoxonase 1 Genetic Polymorphisms and Susceptibility to Breast Cancer: a Meta-analysis

Overview
Publisher Elsevier
Specialties Oncology
Public Health
Date 2011 Dec 3
PMID 22133529
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The paraoxonase 1 gene (PON1, MIN: 168820) is a member of the multifactorial antioxidant enzyme paraoxonase family (EC 3.1.1.2). Two common functional single-nucleotide polymorphisms L55M (dbSNP: rs854560) and Q192R (dbSNP: rs662) have been identified in the coding region of PON1. Several studies have investigated the associations between polymorphisms of PON1 and susceptibility to breast cancer, but have yielded apparently conflicting results. We therefore carried out a meta-analysis of published studies to clarify this inconsistency and to establish a comprehensive picture of the relationship between PON1 gene variants and breast cancer risk.

Method: Overall six eligible studies were identified. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were obtained using fixed and random-effect models.

Results: In our meta-analysis, the presence of the R allele was associated with decreased risk of breast cancer (QR+RR compared to QQ genotype, summary OR=0.57, 95% CI: 0.49-0.67, P<0.001). Both heterozygosity (OR=1.32, 95% CI: 1.10-1.58, P=0.002) and homozygosity (OR=2.16, 95% CI: 1.75-2.68, P<0.001) for the 55M allele were associated with increased risk of breast cancer. Also there was a significant linear trend in risk associated with zero, one, and two 55M alleles (χ(2)=54.2, P<0.001).

Conclusion: The present study showed that PON1 M and Q alleles are associated with a higher risk of breast cancer. Individuals having MM and QQ genotypes have a lower level and lower detoxification activity of the PON1 enzyme, which may increase the vulnerability of the breast to genetic damage by reducing the ability to detoxify inflammatory oxidants, as well as dietary carcinogens.

Citing Articles

The Relationship between Cancer and Paraoxonase 1.

Medina-Diaz I, Ponce-Ruiz N, Rojas-Garcia A, Zambrano-Zargoza J, Bernal-Hernandez Y, Gonzalez-Arias C Antioxidants (Basel). 2022; 11(4).

PMID: 35453382 PMC: 9028432. DOI: 10.3390/antiox11040697.


Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma.

Xu D, Wang Y, Wu J, Lin S, Chen Y, Zheng J Cancer Cell Int. 2021; 21(1):621.

PMID: 34819088 PMC: 8613962. DOI: 10.1186/s12935-021-02326-8.


Association of PON1, LEP and LEPR Polymorphisms with Susceptibility to Breast Cancer: A Meta-Analysis.

Sayad S, Dastgheib S, Farbod M, Asadian F, Karimi-Zarchi M, Salari S Asian Pac J Cancer Prev. 2021; 22(8):2323-2334.

PMID: 34452542 PMC: 8629481. DOI: 10.31557/APJCP.2021.22.8.2323.


Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.

Marinko T, Stojanov Konda J, Dolzan V, Goricar K Dis Markers. 2021; 2020:6645588.

PMID: 33425072 PMC: 7772014. DOI: 10.1155/2020/6645588.


The Role of Variants in Disease Susceptibility in a Turkish Population.

Abudayyak M, Boran T, Tukel R, Oztas E, Ozhan G Glob Med Genet. 2020; 7(2):41-46.

PMID: 32939514 PMC: 7490120. DOI: 10.1055/s-0040-1715568.